Is Medplus Health Services a Good Buy After Its Q1 FY27 Results?
- September 4, 2026
- Posted by: Lakshit Sharma
- Category: Market
Medplus Health Services share price around Rs 662. 35.2% below 52-week high of Rs 1,022. Q1 FY27 revenue Rs 1,899 crore, up 21.9% YoY. PAT Rs 33 crore, down 21.7%. PE 38x.
Quick Answer
Medplus Health Services’ Q1 FY27 results were mixed, with revenue at Rs 1,899 crore but PAT falling 22% to Rs 33 crore. The Medplus Health Services share price near Rs 662 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Medplus Health Services is a good buy right now.
The Medplus Health Services share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Medplus Health Services is one of India’s largest pharmacy retail chains, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 1,899 crore, up 21.9% year on year, while profit after tax came in at Rs 33 crore, down 21.7% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Medplus Health Services share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Medplus Health Services share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Medplus Health Services Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 1,899 crore | Rs 1,558 crore | 21.9% |
| EBITDA | Rs 153 crore | Rs 146 crore | 5.0% |
| Operating Margin | 8.1% | 9.4% | NA |
| Profit Before Tax | Rs 42 crore | Rs 53 crore | -20.6% |
| Net Profit / (Loss) | Rs 33 crore | Rs 42 crore | -21.7% |
Medplus Health Services Q1 FY27 Performance Analysis
Check Medplus Health Services Fundamentals on Univest Screener
Revenue growth of 21.9% for the quarter came from steady demand across the company’s core business, keeping the topline trend intact for the pharmacy retail sector.
Profitability is where the quarter disappointed. PAT fell 22% year on year to Rs 33 crore even as revenue grew, which points to margin or cost pressure that management will need to address. This gap between top-line and bottom-line performance is the key thing weighing on the Medplus Health Services share price this quarter.
On a sequential basis, revenue moved up 0.8% sequentially from Rs 1,885 crore in the March 2026 quarter and net profit moved down 48.1% sequentially from Rs 64 crore in the prior quarter, giving a fuller picture of the trend behind the Medplus Health Services share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Medplus Health Services’ revenue grew 21.9% year on year this quarter, taking the quarterly base to Rs 1,899 crore in a pharmacy retail business that remains sensitive to demand and pricing cycles that ultimately feed through to the Medplus Health Services share price.
Margin Movement
EBITDA rose 5.0% to Rs 153 crore, and operating margin moved to 8.1% from 9.4% a year earlier, a sign that cost control or pricing held up during the quarter.
Balance Sheet Position
Medplus Health Services’ debt-to-equity ratio stands at 0.72, a level worth monitoring given the quarter’s margin trend.
Valuation Context
The stock trades at a PE of 37.8x, below the industry average of 68.9x, which is worth factoring into any read of whether the Medplus Health Services share price is expensive or reasonably priced.
Dividend Details
No interim dividend was declared alongside Medplus Health Services’ Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Medplus Health Services share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Medplus Health Services Share Price Outlook for FY27
The key question for the rest of FY27 is whether Medplus Health Services can arrest the margin pressure seen this quarter. Revenue growth alone will not be enough to support the Medplus Health Services share price if profitability keeps slipping, so investors should watch the next couple of quarters for signs of a turnaround in the bottom line.
A stabilising or improving margin trend in the next result would be the clearest signal that this quarter’s profit decline was a temporary setback rather than the start of a longer slide for the Medplus Health Services share price.
Medplus Health Services Stock Performance
Download the Univest iOS App or Univest Android App to track Medplus Health Services’ live share price and get daily stock updates.
The Medplus Health Services share price was trading around Rs 662 as results season played out in late August 2026, roughly 35.2% below its 52-week high of Rs 1,022 and hovering just above its 52-week low of Rs 648. Promoter holding stood at 40.2% as of the June 2026 quarter.
The Medplus Health Services share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 11.12% and a book value of around Rs 164 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Profitability Risk
The quarter’s profit trend is the clearest risk here. Until Medplus Health Services shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.
Leverage Risk
A debt-to-equity ratio of 0.72 means the company’s earnings are more sensitive to interest rate and refinancing conditions than a lower-debt peer.
Sector and Demand Risk
As a pharmacy retail business, Medplus Health Services’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Medplus Health Services share price well before the next result.
Conclusion
Medplus Health Services’ Q1 FY27 results show a business still growing its top line but losing ground on profitability, with PAT down 22% to Rs 33 crore even as revenue rose. The Medplus Health Services share price reflects a stock in wait-and-watch mode, and it is not an obvious buy purely on this quarter’s numbers until the margin trend turns around.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Medplus Health Services Q1 FY27 Results
What were Medplus Health Services’ Q1 FY27 results?
Ans. Medplus Health Services reported Q1 FY27 revenue of Rs 1,899 crore, up 21.9% year on year, and PAT of Rs 33 crore, down 21.7% year on year.
Is Medplus Health Services a good buy after its Q1 FY27 results?
Ans. Medplus Health Services’ profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.
What is the Medplus Health Services share price today?
Ans. The Medplus Health Services share price was trading around Rs 662 in late August 2026, about 35.2% below its 52-week high of Rs 1,022 and well above its 52-week low of Rs 648.
What is Medplus Health Services’ revenue and profit for Q1 FY27?
Ans. Medplus Health Services reported revenue of Rs 1,899 crore and a net profit of Rs 33 crore for the quarter ended June 30, 2026.
Did Medplus Health Services declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Medplus Health Services’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Medplus Health Services’ PE ratio and is it expensive?
Ans. The Medplus Health Services share price trades at a trailing PE of 37.8x, against an industry average of 68.9x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Medplus Health Services investors right now?
Ans. The quarter’s profit trend is the clearest risk here. Until Medplus Health Services shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. As a pharmacy retail business, Medplus Health Services’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Medplus Health Services share price well before the next result.
What is Medplus Health Services’ promoter shareholding?
Ans. Promoter holding in Medplus Health Services stood at 40.2% as of the June 2026 quarter.